Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? (Q37744997)

22 August 2017

1 reference

title

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? (English)

1 reference

22 August 2017

1 reference

Kevin S Clive

1

1 reference

22 August 2017

Josh A Tyler

2

1 reference

22 August 2017

G Travis Clifton

3

1 reference

22 August 2017

Jarrod P Holmes

4

1 reference

22 August 2017

Elizabeth A Mittendorf

5

1 reference

22 August 2017

Sathibalan Ponniah

6

1 reference

22 August 2017

George E Peoples

7

1 reference

22 August 2017

language of work or name

1 reference

1 May 2010

1 reference

Expert Review of Vaccines

22 August 2017

published in

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

519-525

1 reference

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

22 August 2017

cites work

1 reference

Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and t

21 January 2018

1 reference

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

21 January 2018

1 reference

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine

21 January 2018

1 reference

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion

21 January 2018

1 reference

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

21 January 2018

1 reference

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

21 January 2018

1 reference

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group

21 January 2018

1 reference

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

21 January 2018

1 reference

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

21 January 2018

1 reference

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.10.40

1 reference

22 August 2017

1 reference